James C Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3880725/publications.pdf

Version: 2024-02-01

933447 888059 21 352 10 17 h-index citations g-index papers 22 22 22 570 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Changing from mandatory to optional genotyping results in higher acceptance of pharmacist-guided warfarin dosing. Pharmacogenomics, 2022, 23, 85-95.	1.3	1
2	<i>CYP2C19</i> Genotypeâ€Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. Journal of the American Heart Association, 2022, 11, e024159.	3.7	24
3	Impact of the <i>CYP2C19*17</i> Allele on Outcomes in Patients Receiving Genotypeâ€Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Clinical Pharmacology and Therapeutics, 2021, 109, 705-715.	4.7	25
4	Meta-analysis comparing direct oral anticoagulants versus vitamin K antagonists in patients with left ventricular thrombus. PLoS ONE, 2021, 16, e0252549.	2.5	11
5	Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. Genetics in Medicine, 2021, 23, 2335-2341.	2.4	32
6	Genotype-Guided vs Clinically-Guided Stable Warfarin Dose Prediction and Stable Dose Establishment In A Predominantly Non-European Ancestry Population. Expert Review of Precision Medicine and Drug Development, 2021, 6, 375-379.	0.7	0
7	Applicability of Pharmacogenomically Guided Medication Treatment during Hospitalization of At-Risk Minority Patients. Journal of Personalized Medicine, 2021, 11, 1343.	2.5	2
8	Use of Direct Oral Anticoagulants in Morbidly Obese Patients. Pharmacotherapy, 2020, 40, 72-83.	2.6	30
9	Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability. Pharmacotherapy, 2020, 40, 704-712.	2.6	14
10	Effect of <i>CYP2C9 *11/*11</i> genotype on initial and long-term warfarin dose requirement and therapeutic response. Pharmacogenomics, 2020, 21, 1271-1277.	1.3	2
11	Precision pharmacotherapy: Integrating pharmacogenomics into clinical pharmacy practice. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 303-313.	1.0	45
12	Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genetics in Medicine, 2019, 21, 2255-2263.	2.4	53
13	PRN OPINION PAPER: Application of precision medicine across pharmacy specialty areas. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 288-302.	1.0	10
14	Best practices: Incorporating pharmacy technicians and other support personnel into the clinical pharmacist's process of care. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 74-81.	1.0	14
15	Clinical and Financial Outcomes Evaluation of Multimodal Pharmacist Warfarin Management of a Statewide Urban and Rural Population. Journal of Pharmacy Practice, 2018, 31, 150-156.	1.0	10
16	Quality of Pharmacist-Managed Anticoagulation Therapy in Long-Term Ambulatory Settings: A Systematic Review. Annals of Pharmacotherapy, 2017, 51, 1122-1137.	1.9	61
17	Clinical effect of CYP2C9*5/*6genotype on a patient's warfarin dose requirement. Pharmacogenomics, 2017, 18, 1051-1057.	1.3	6
18	Patient-Centered Strategies for Improving Warfarin Management., 2017,, 101-108.		0

#	Article	IF	CITATIONS
19	Oral Anticoagulants in Patients with Variable Renal Function. , 2017, , 61-68.		0
20	The evolving role of dabigatran etexilate in clinical practice. Expert Opinion on Pharmacotherapy, 2015, 16, 2053-2072.	1.8	0
21	Comparison of warfarin therapy clinical outcomes following implementation of an automated mobile phone-based critical laboratory value text alert system. BMC Medical Genomics, 2014, 7, S13.	1.5	12